title: Pharmaceutical cocrystals: the coming wave of new drug substances.
abstract: Solid crystalline phases containing two cocrystallized components offer a new development pathway whereby one can potentially improve the physical characteristics (i.e., equilibrium solubility, dissolution rate, solid-state stability, etc.) of a drug substance that exhibits a profile that is less than desirable. In this commentary, the topic of pharmaceutical cocrystals will be briefly explored, and a short exposition of the solubility and dissolution rate advantages that have been realized in various systems will be provided. The Guidance for Industry document recently proposed by United States Food and Drug Administration will be outlined, and its requirements explained. Finally, the subset of pharmaceutical cocrystals that consist of a drug substance and a salt of that substance (termed a salt cocrystal) will be examined to illustrate this additional class of pharmaceutical cocrystals that may offer significant scientific and regulatory advantages.
authors.affiliation: Center for Pharmaceutical Physics, Milford, New Jersey 08848, USA. hbrittain@centerpharmphysics.com
authors.forename: Harry G
authors.initials: HG
authors.lastname: Brittain
mesh_terms: D000818:Animals; D001682:Biological Availability; D002626:Chemistry, Pharmaceutical / Q000379:methods* / Q000639:trends; D003460:Crystallization; D006801:Humans; D004364:Pharmaceutical Preparations / Q000008:administration & dosage* / Q000737:chemistry*; D012995:Solubility
chemical_list: D004364:Pharmaceutical Preparations